beliver.fr

What It Is

BeLiver is a predictive oncology project rooted in France’s research and hospital ecosystem, positioned as an AI-assisted tool for selecting cancer treatments. Its first major focus is LiverWise, a liver cancer service that analyzes high-resolution proteomics data from tumor biopsy samples and uses machine learning to generate personalized treatment response reports. The goal is to help physicians assess a patient’s potential benefit from chemotherapy, targeted therapy, and immunotherapy.

Core Capabilities and Output

Based on publicly available information, BeLiver’s differentiation is not a general-purpose large model, but vertical medical modeling built around “proteomics + AI.” It aims to capture the functional state of tumors and their microenvironment, then have models interpret multi-protein signatures and produce treatment guidance reports for clinicians. The company highlights compatibility with small fixed biopsy samples, integration into existing workflows, and a design target of returning a comprehensive report within one week. The platform may also be used for discovering new protein targets, patient stratification, and research collaborations with pharmaceutical companies.

Pricing and Availability

The biggest current limitation is commercial availability. The website clearly states that BeLiver’s service is still under development, is not yet commercially available, and has not obtained CE marking under the European IVDR regulatory framework. As a result, the public pages do not constitute a commercial offer or medical advice, and pricing, trials, and payment methods have not been disclosed. For hospitals or pharmaceutical companies, the more realistic route at this stage is collaborative R&D or clinical research partnership rather than direct procurement.

Pros and Cons

The main strengths are its focus on liver cancer, a high-value area with limited reliable biomarkers and highly variable treatment responses; its technical approach, which emphasizes functional proteomic signals and has some potential for clinical translation; and a team background spanning oncology practice, proteomics, mass spectrometry, and AI modeling. The drawbacks are equally clear: it does not disclose model performance, validation cohorts, clinical trial results, or real-world evidence; it does not explain data privacy, hospital system integration, APIs, or compliance details; and at this stage it cannot replace physician judgment or be used as an approved diagnostic product.

Who It’s For and Access from China

BeLiver is more relevant for oncologists, hospitals, research institutions, pharmaceutical companies, and precision medicine teams—especially organizations interested in liver cancer treatment prediction, patient stratification, or protein target discovery. For ordinary patients or clinical institutions looking for an immediately available testing service, the current information is insufficient. Access from China, payment options, and local compliance status are unknown. Because human samples and medical data are involved, cross-border sample handling, data export, and medical device registration requirements would also need additional assessment. Alternative options include approved local oncology companion diagnostics, NGS testing services, and in-hospital precision medicine platforms.